Skip to main content
TipRanks
Go Ultimate75% OFF

Novacyt (ALNOV) AI Stock Analysis

11 Followers
FR:ALNOV

Novacyt

(Paris:ALNOV)

Select Model
Rating:46Neutral
Price Target:EUR 0.40â–¼(-10.67% Downside)
Action:reiterated
Date:10/16/26

The score is held down primarily by weak financial performance—persistent large losses, multi-year cash burn, and rising balance-sheet pressure—despite improving revenue and gross margin. Technicals are neutral-to-soft with only modest support from longer-term averages. The latest earnings call adds some upside via continued revenue growth, a long-term Illumina partnership, and restructuring guidance toward lower cash burn, but execution and profitability remain the central risks.

Positive Factors
Sustained Revenue GrowthRevenue growth has continued across three consecutive half-years, while the underlying business expanded even excluding the Southern Cross contribution. This indicates improving commercial traction and broader demand, providing a stronger base for future scale if growth remains balanced across regions and products.
Negative Factors
Persistent UnprofitabilityNovacyt remains deeply loss-making despite the revenue rebound, showing that current scale and pricing are insufficient to cover the cost base. Persistent operating losses limit internally funded investment, make execution more dependent on restructuring, and leave profitability as the central fundamental risk.

Novacyt (ALNOV) vs. iShares MSCI France ETF (EWQ)

-50%-25%0%25%50%75%100%125%FR:ALNOV+4.65%EWQ+2.46%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 41.38M
Dividend Yield
―
Average Volume (3M)
230.46K
Price to Earnings (P/E)
-0.8
Beta (1Y)
0.16
Revenue Growth
10.36%
EPS Growth
29.41%
Country
France
Employees
228
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Novacyt Business Overview & Revenue Model

Company Description

Founded in 2006 and headquartered in Vélizy-Villacoublay, France, Novacyt S.A. and its subsidiaries are actively involved in the full lifecycle of diagnostic products, encompassing development, manufacturing, custom design, and global commercializati...

How the Company Makes Money

Novacyt makes money primarily by selling in-vitro diagnostic (IVD) products and related consumables to laboratories, hospitals, and other healthcare/testing customers. Key revenue streams typically include: (1) sales of molecular diagnostic test kits...

Novacyt Earnings Call Summary

Earnings Call Date:Sep 30, 2026(Q2-2026)|% Change Since:-11.07%|Next Earnings Date:Jun 22, 2021
Earnings Call SentimentPositive

The call was predominantly positive. Management highlighted 18% year-on-year revenue growth, three consecutive half-years of growth, broad geographic and product expansion, the Southern Cross contribution, the DPYD launch, the five-year Illumina agreement and substantial operating-cost reductions. The principal negatives were the decline in gross margin to 56%, lower RUO sales, continued EBITDA losses, cash consumption and an incomplete restructuring program. Management characterized the cost actions as on plan and said cash burn should materially decline after restructuring.

Positive Updates

Revenue Growth Continued
H1 revenue increased significantly to GBP 11.6 million. Excluding Southern Cross Diagnostics, the underlying business still grew by around 9%. Management also reported 18% year-on-year growth for the period and three consecutive half-years of growth, from GBP 9.6 million in H2 2024 through H1 2026.

Negative Updates

Gross Margin Declined
Gross profit was broadly flat at around GBP 6.4 million, while gross margin declined by around 10 percentage points to 56%. Management attributed the reduction to the lower-margin Southern Cross distributor sales, which caused about 3 percentage points of dilution; a fair-value uplift on Southern Cross opening inventory, which caused another approximately 3 percentage points of dilution; and reduced sales of the over-80%-gross-margin Primerdesign business as a proportion of total revenue. Management expects the stock uplift of around GBP 0.5 million to be fully released in the 2026 financial results and continues to expect long-term gross margin above 60%.

Company Guidance

Management said the GBP 4 million cost restructuring is on track, with most of the benefit expected in 2027; at the end of September, around 60 staff released represented around a GBP 2.7 million annual reduction in costs, while nonlabor savings were identified at between GBP 0.5 million and around GBP 700,000, for at least around GBP 3.2 million to GBP 3.4 million of savings expected to start flowing through certainly from 2027 onwards, if not very, very soon over the next couple of weeks. The total stock uplift amount is estimated at around GBP 0.5 million, with all of this expected to be released in the 2026 financial results, and longer term the business still expects to deliver a gross margin of over 60%; underlying cash burn is expected to be materially lower once all the restructuring activities have been completed, with benefits starting in the 2027 financial results. The Illumina agreement is for a 5-year period, and management expects this to be a long-term partnership.

Novacyt Financial Statement Overview

Summary

Despite a strong TTM revenue rebound (~+25.9%) and improved gross margin (~44.6%), the company remains deeply loss-making (TTM net margin ~-102%) with continued negative operating and free cash flow (OCF ~-11.9M; FCF ~-12.2M). Balance sheet pressure is rising via higher leverage (~0.55x debt/equity) and shrinking equity, limiting flexibility until profitability and cash generation improve.

Income Statement

24Negative

Balance Sheet

46Neutral

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue32.76M20.40M19.63M11.58M21.04M92.60M
Gross Profit14.62M7.89M32.07M3.73M5.75M63.50M
EBITDA-5.73M-8.21M-9.31M-18.24M-15.47M43.82M
Net Income-33.55M-23.31M-41.76M-28.29M-25.73M-9.73M
Balance Sheet
Total Assets37.47M40.28M70.63M133.81M140.90M183.70M
Cash, Cash Equivalents and Short-Term Investments8.88M19.14M30.46M44.06M86.98M101.75M
Total Debt10.19M10.44M11.88M13.70M872.00K1.87M
Total Liabilities18.85M16.94M22.75M46.57M25.68M41.88M
Stockholders Equity18.62M23.34M47.88M87.24M115.22M141.81M
Cash Flow
Free Cash Flow-12.18M-9.03M-11.01M-25.66M-14.14M11.59M
Operating Cash Flow-11.87M-8.76M-8.49M-24.99M-13.73M15.69M
Investing Cash Flow-8.58M-811.91K-1.86M-13.94M-577.00K-5.03M
Financing Cash Flow-1.58M-1.99M-1.84M-3.97M-516.00K-599.00K

Novacyt Technical Analysis

Technical Analysis SentimentPositive
Last Price0.45

Price Trends

50DMA0.47Negative
100DMA0.46Negative
200DMA0.45Positive

Market Momentum

MACD-0.01Negative
RSI51.30Neutral
STOCH65.45Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALNOV, the sentiment is Positive. The current price of 0.45 is above the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.47, and above the 200-day MA of 0.45, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 51.30 is Neutral, neither overbought nor oversold. The STOCH value of 65.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ALNOV.

Novacyt Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

FR:ALNOV against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
FR:ALERSFR:ALERS58NeutralEUR 259.38M37.713.89%―6.28%204.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
FR:ALIKOFR:ALIKO46NeutralEUR 22.89M-5.31-22.49%―37.28%7.83%
FR:ALMKTFR:ALMKT46NeutralEUR 18.02M1.46-157.72%―3.38%―
FR:ALNOVFR:ALNOV46NeutralEUR 32.66M-0.78-159.70%―10.36%29.41%
FR:ALMDTFR:ALMDT43NeutralEUR 213.68M-3.54271.64%―2.16%-5.26%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%FR:ALNOVFR:ALMKTFR:ALERSFR:ALDMSFR:ALIKOFR:ALMDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
FR:ALNOV and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
FR:ALNOVNovacyt S.A.0.450.023.45%
FR:ALMKTMAUNA KEA TECHNOLOGIES0.090.0110.98%
FR:ALERSEurobio-Scientific SA26.352.209.11%
FR:ALDMSDiagnostic Medical Systems0.91-0.36-28.19%
FR:ALIKOIkonisys SA1.460.021.74%
FR:ALMDTMedian Technologies4.281.3545.83%

Novacyt Corporate Events

Novacyt Reports October Liquidity Activity and Voting Rights

Nov 2, 2026

Novacyt reported that Invest Securities bought 118,300 ordinary shares and sold 67,005 shares under the company’s liquidity contract during October 2026. The activity left Novacyt holding 116,872 shares in treasury at the end of the month, supporting...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 16, 2026